 Vident Investment Advisory LLC acquired a new stake in shares of Adaptimmune Therapeutics PLC NASDAQ:ADAP in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission SEC. The firm acquired 140,529 shares of the biotechnology companys stock, valued at approximately 1,406,000. Several other institutional investors ... 